Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)

Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision impairment. Historically, the VEGF inhibitors Eylea, Lucentis, and off-label Avastin have formed the foundation of firstline DME management. Corticosteroid implants like Ozurdex and Iluvien are typically introduced in later treatment stages, particularly for patients with an incomplete response to anti-VEGF therapy. Although Novartis’ Beovu entered the market as an additional option, its adoption has remained limited due to safety considerations. The therapeutic landscape has expanded in recent years with the introduction of innovative agents such as Roche’s Vabysmo and Susvimo, as well as Regeneron’s Eylea HD, all designed to reduce patients’ treatment burden. Competition has intensified further with the launch of biosimilar versions of Lucentis and Eylea, delivering comparable efficacy at a lower cost and broadening access to effective DME treatment.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
• How has Eylea HD been integrated into the treatment algorithm, and what is its source of business?
• What percentage of DME patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of DME patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Eylea, Lucentis, Avastin, Eylea HD, Vabysmo, Ozurdex

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.